Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
HCV
OAT
PWID
SVR
adherence pattern
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
17
12
2020
pubmed:
21
4
2021
medline:
15
3
2022
entrez:
20
4
2021
Statut:
ppublish
Résumé
Adequate medication adherence is critical for achieving sustained viral response (SVR) of hepatitis C virus (HCV) among people who inject drugs (PWID). However, it is less known which patterns of direct-acting antiviral (DAA) treatment adherence are associated with SVR in this population or what factors are associated with each pattern. The randomized 3-arm PREVAIL study used electronic blister packs to obtain daily time frame adherence data in opiate agonist therapy program settings. Exact logistic regressions were applied to test the associations between SVR and 6 types of treatment adherence patterns. Of the 113 participants treated with combination DAAs, 109 (96.5%) achieved SVR. SVR was significantly associated with all pattern parameters except for number of switches between adherent and missed days: total adherent daily doses (exact adjusted odds ratio [AOR] = 1.12; 95% confidence interval [CI] = 1.04-1.22), percent total doses (1.09; 1.03-1.16), days on treatment (1.16; 1.05-1.32), maximum consecutive adherent days (1.34; 1.06-2.04), and maximum consecutive nonadherent days (0.85; .74-.95 = 0.003). SVR was significantly associated with total adherent doses in the first 2 months of treatment, it was not in the last month. While alcohol intoxication was significantly associated with frequent switches, drug use was not associated with any adherence pattern. Consistent maintenance of adequate total dose adherence over the entire course of HCV treatment is important in achieving SVR among PWID. Additional integrative addiction and medical care may be warranted for treating PWID who experience alcohol intoxication.
Sections du résumé
BACKGROUND
Adequate medication adherence is critical for achieving sustained viral response (SVR) of hepatitis C virus (HCV) among people who inject drugs (PWID). However, it is less known which patterns of direct-acting antiviral (DAA) treatment adherence are associated with SVR in this population or what factors are associated with each pattern.
METHODS
The randomized 3-arm PREVAIL study used electronic blister packs to obtain daily time frame adherence data in opiate agonist therapy program settings. Exact logistic regressions were applied to test the associations between SVR and 6 types of treatment adherence patterns.
RESULTS
Of the 113 participants treated with combination DAAs, 109 (96.5%) achieved SVR. SVR was significantly associated with all pattern parameters except for number of switches between adherent and missed days: total adherent daily doses (exact adjusted odds ratio [AOR] = 1.12; 95% confidence interval [CI] = 1.04-1.22), percent total doses (1.09; 1.03-1.16), days on treatment (1.16; 1.05-1.32), maximum consecutive adherent days (1.34; 1.06-2.04), and maximum consecutive nonadherent days (0.85; .74-.95 = 0.003). SVR was significantly associated with total adherent doses in the first 2 months of treatment, it was not in the last month. While alcohol intoxication was significantly associated with frequent switches, drug use was not associated with any adherence pattern.
CONCLUSIONS
Consistent maintenance of adequate total dose adherence over the entire course of HCV treatment is important in achieving SVR among PWID. Additional integrative addiction and medical care may be warranted for treating PWID who experience alcohol intoxication.
Identifiants
pubmed: 33876230
pii: 6238636
doi: 10.1093/cid/ciab334
pmc: PMC8664449
doi:
Substances chimiques
Analgesics, Opioid
0
Antiviral Agents
0
Banques de données
ClinicalTrials.gov
['NCT01857245']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2093-2100Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA053730
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA043011
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA034086
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Drug Alcohol Depend. 2017 Aug 1;177:214-220
pubmed: 28618285
BMC Public Health. 2020 Jan 20;20(1):81
pubmed: 31959145
Int J Drug Policy. 2017 Sep;47:202-208
pubmed: 28619394
Am J Gastroenterol. 2006 Oct;101(10):2254-62
pubmed: 17032190
Open Forum Infect Dis. 2020 Jul 20;7(8):ofaa290
pubmed: 32818140
PLoS One. 2017 Jun 21;12(6):e0178398
pubmed: 28636638
Antiviral Res. 2014 Apr;104:62-72
pubmed: 24468275
J Subst Abuse Treat. 2017 Apr;75:49-53
pubmed: 28237054
Int J Drug Policy. 2017 Sep;47:209-215
pubmed: 28587943
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
J Antimicrob Chemother. 2011 Aug;66(8):1673-86
pubmed: 21652618
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
South Med J. 2018 Jan;111(1):45-50
pubmed: 29298369
Int J Clin Pract. 2012 Apr;66(4):342-55
pubmed: 22420497
BMJ Open. 2020 Aug 26;10(8):e036355
pubmed: 32847908
Clin Infect Dis. 2014 Nov 15;59(10):1411-9
pubmed: 25114031
Aliment Pharmacol Ther. 2016 Mar;43(6):674-96
pubmed: 26787287
Dig Dis Sci. 2014 Apr;59(4):872-80
pubmed: 24532254
Hepatology. 2019 Feb;69(2):487-497
pubmed: 28749564
Addiction. 2008 Jun;103(6):905-18
pubmed: 18422827
Hepatology. 2018 Sep;68(3):827-838
pubmed: 29377196
BMJ Open. 2016 Dec 20;6(12):e014194
pubmed: 27998903
Gut. 2012 May;61 Suppl 1:i36-46
pubmed: 22504918
JAMA. 2012 Dec 26;308(24):2584-93
pubmed: 23268517
Int J Drug Policy. 2018 Dec;62:14-23
pubmed: 30352330
Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa377
pubmed: 33134406
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
Aliment Pharmacol Ther. 2020 Jun;51(12):1384-1396
pubmed: 32352586
Clin Infect Dis. 2020 Oct 23;71(7):1715-1722
pubmed: 32009165
BMC Infect Dis. 2018 Feb 9;18(1):74
pubmed: 29426304
J Gen Intern Med. 2020 Apr;35(4):1011-1020
pubmed: 31659661
J Infect Dis. 2020 Jul 6;222(3):488-498
pubmed: 32150621
J Viral Hepat. 2021 Mar;28(3):548-557
pubmed: 33249689
Liver Int. 2016 Jan;36 Suppl 1:47-57
pubmed: 26725897
Open Forum Infect Dis. 2020 Nov 19;8(1):ofaa564
pubmed: 33447634
Ann Intern Med. 2019 May 7;170(9):594-603
pubmed: 30959528
Clin Infect Dis. 2020 Oct 23;71(7):e115-e124
pubmed: 31677262
Gastroenterology. 2018 Mar;154(4):976-988.e4
pubmed: 29146520
J Am Pharm Assoc (2003). 2019 Jan - Feb;59(1):51-56
pubmed: 30545782
Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6
pubmed: 25245939